PVX-7 is under clinical development by Papivax and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II drugs for Oropharyngeal Cancer have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PVX-7’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PVX-7 overview
PVX7 is under development for the treatment of human papillomavirus (HPV)-associated cervical cancer, cervical intraepithelial neoplasia and oropharyngeal cancer. The vaccine candidate comprises of self-adjuvanting pBI-11 DNA plasmid vector (Sig-E7HPV16-E7HPV18-E6HPV16-E6HPV18-HSP70) encoding E6 and E7 genes of both HPV16 and HPV18. It is administered through intramuscular and intradermal route as heterologous prime-boost immunization regimen, where PVX7 as prime vaccine is followed by TA-HPV (recombinant vaccinia viral vector) as booster vaccine.
For a complete picture of PVX-7’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
